[ad_1]
NEW YORK, April 14, 2019 / PRNewswire / – "The CREDENCE test data released today in the New England Journal of Medicine demonstrate that INVOKANA® (Canagliflozin) may help reduce the risk of end-stage renal failure and cardiovascular events in patients already with type 2 diabetes and chronic renal failure. If this additional indication is approved by the Food and Drug Administration (FDA), it would be the first new treatment for diabetic kidney failure (DKD) for decades. "
"Chronic renal failure is a largely invisible and growing public health problem, with limited treatment options. The announcement of today's study is encouraging for patients with diabetic nephropathy and is an important step forward in preventing chronic renal failure. It is important for patients to note that while this announcement is promising, they should continue to consult their doctor to find out what treatment is right for them. "
"Diabetes is a key risk factor for chronic renal failure and accounts for 44% of all cases of end-stage renal failure, however, less than 40% of people with diabetes are fully evaluated for kidney failure." Two simple tests, an eGFR (which evaluates kidney function) and an ACR (which badesses kidney damage) can diagnose kidney disease, and the results of these tests are also powerful predictors of cardiovascular risk.Chronic Renal Disease Change Package: Population Health Strategies for Reducing Risk of Cardiovascular and Renal Diseases"report for clinicians and public health practitioners announced in January 2019. "
Facts about kidney disease
In United States It is estimated that 30 million adults suffer from chronic kidney failure – and most do not know it. One in three American adults is at risk for chronic kidney disease. Diabetes, hypertension, heart disease, obesity and family history are risk factors for kidney failure. People of African American, Hispanic, Native American, Asian or Pacific Island descent are at increased risk of developing the disease. African-Americans are three times more likely than whites, and Hispanics are nearly 1.5 times more likely than non-Hispanics to develop end-stage renal failure (renal failure).
The National Kidney Foundation (NKF) is the largest, most comprehensive and oldest organization dedicated to the awareness, prevention and treatment of kidney disease. For more information on the NKF, visit www.kidney.org.
Facebook.com
Twitter: @NKF
www.kidney.org
SOURCE National Kidney Foundation
Related Links
http://www.kidney.org
[ad_2]
Source link
